ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2023

Abstract Number: 0620

Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry

Isha Lamba1, Ashima Makol2, Dinesh Khanna3, John VanBuren4, Angela Child4, Jessica Alvey4, Shervin Assassi5, Elana Bernstein6, Flavia Castelino7, Lorinda Chung8, Luke Evnin9, Tracy Frech10, Faye Hant11, Laura Hummers12, Kimberly Lakin13, Dorota Lebiedz-Odrobina14, Yiming Luo15, Jerry Molitor16, Duncan Moore17, Carrie Richardson18, Nora Sandorfi19, Ami Shah20, Ankoor Shah21, Victoria Shanmugam22, Brian Skaug23, Virginia Steen24, Elizabeth Volkmann25 and Jessica Gordon13, 1New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3University of Michigan, Ann Arbor, MI, 4University of Utah, Salt Lake City, UT, 5University of Texas McGovern Medical School at Houston, Houston, TX, 6Columbia University, New York, NY, 7Massachusetts General Hospital, Boston, MA, 8Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 9Scleroderma Research Foundation, Brisbane, CA, 10Vanderbilt University Medical Center, Nashville, TN, 11Medical University of South Carolina, Charleston, SC, 12Johns Hopkins University, Baltimore, MD, 13Hospital for Special Surgery, New York, NY, 14University of Utah, Cottonwood Heights, UT, 15Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 16University of Minnesota, Minneapolis, MN, 17Northwestern Memorial Hospital, Chicago, IL, 18Northwestern University, Riverside, IL, 19University of Pennsylvania, Philadelphia, PA, 20Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 21Duke University, Durham, NC, 22Victoria Shanmugam, MD, Great Falls, VA, 23Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 24Georgetown University School of Medicine, Washington, DC, 25University of California Los Angeles, Los Angeles, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2023

Keywords: Patient reported outcomes, physical function, quality of life, risk assessment, Systemic sclerosis

Session Information

Date: Sunday, November 12, 2023

Title: (0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient-Reported Outcomes Measurement Information System-29 version 2.0 (PROMIS-29v2) is a patient-centered questionnaire used to assess health-related quality of life (HRQoL). PROMIS-29v2 has shown validity and responsiveness to change in patients with systemic sclerosis (SSc) but has not yet been described specifically in early SSc. This study’s aim was to describe PROMIS-29v2 outcomes and clinical associations in the Collaborative National Quality and Efficacy Registry (CONQUER), which is a multi-center US-based registry of patients with early limited cutaneous (lc) and diffuse cutaneous (dc) SSc.

Methods: Patients enrolled in CONQUER meet 2013 ACR-EULAR Classification criteria for SSc and have a disease duration of less than 5 years from their first non-Raynaud SSc symptom. Baseline results of the PROMIS-29v2 domains of physical function (PF), ability to participate in social roles/activities or social function (SF), pain interference, fatigue, anxiety/fear, sleep disturbance, and depression were described for the entire CONQUER cohort and compared between patients with lcSSc and dcSSc using two-sample t-tests. Pearson’s correlation assessed the relationship between patient clinical characteristics and PROMIS-29v2 domain scores.

Results: Baseline data were available for 536 participants. Of these, 368 (68.7%) had dcSSc (Table 1). Disease duration from first non-Raynaud’s symptom was 2.6 [1.3, 3.8] years for the whole group and was not significantly different between lcSSc and dcSSc. Individuals with dcSSc had worse PF, SF and pain interference, but significant differences were not seen for fatigue, anxiety/fear, sleep disturbance and depression (Table 1). Female participants had significantly higher anxiety/fear, 54.1 (95% CI 40.3, 60.3) versus 44.1 (40.3, 57.5) for males, p=0.001 (Table 2). PF score was worse (lower) in participants with digital ulcers, restrictive lung disease (RLD, defined as FVC < 70% or TLC < 80%) and pulmonary hypertension. The presence of digital ulcers correlated with worse scores in multiple domains, including PF, SF, pain interference and depression/sadness. RLD correlated with worse PF and SF. Higher mRSS was weakly correlated with PF, r = -0.38 (95% CI -0.45, -0.3) and SF, r = -0.27 (-0.35, -0.19) in the whole group and in the dcSSc group (Table 3). Statistically significant correlations of variable strengths were seen with the UCLA SCTC GIT 2.0 score in all domains (Table 3). The strongest correlations for GIT were seen with fatigue, r = 0.53 (0.46, 0.59); pain interference, r = 0.46 (0.39, 0.52), and SF, r = -0.42 (-0.48, -0.34). Musculoskeletal manifestations including the presence of large or small joint contractures, tendon friction rubs, proximal muscle weakness, calcinosis and the use of ambulatory aids were associated with worse scores in multiple domains (data not shown).

Conclusion: We describe the use of PROMIS-29v2 to assess quality of life in an early US-based SSc cohort. Diffuse disease, higher mRSS, musculoskeletal manifestations, presence of digital ulcers, RLD and UCLA SCTC GIT scores were associated with reduced HRQoL as measured by PROMIS-29v2. Multivariable analysis and assessment of longitudinal change are underway.

Supporting image 1

Table 1

Supporting image 2

Table 2

Supporting image 3

Table 3


Disclosures: I. Lamba: None; A. Makol: Boehringer-Ingelheim, 1, Sanofi-Genzyme, 1; D. Khanna: AbbVie, 12, DSMB, AstraZeneca, 2, Boehringer-Ingelheim, 2, Bristol-Myers Squibb, 2, 5, CSL Behring, 2, Genentech, 2, Horizon Therapeutics, 2, 5, Janssen, 2, 6, Pfizer, 5, Prometheus, 2; J. VanBuren: None; A. Child: None; J. Alvey: None; S. Assassi: AstraZeneca, 2, aTyr, 2, Boehringer Ingelheim, 2, 5, CSL Behring, 2, Janssen, 5, Merck, 2, Momenta, 5, TeneoFour, 2; E. Bernstein: None; F. Castelino: Boehringer-Ingelheim, 2, Genentech, 5, Prometheus, 5; L. Chung: Eicos Science, 1, 2, Eli Lilly, 1, 2, Genentech, 1, 2, IgM biosciences, 1, 2, Janssen, 1, 2, Kyverna, 1, 2, Mitsubishi Tanabe, 1, 2; L. Evnin: None; T. Frech: None; F. Hant: None; L. Hummers: AbbVie/Abbott, 1, Biotest, 2, Boehringer-Ingelheim, 1, 5, CSL Behring, 1, Cumberland Pharmaceuticals, 5, GlaxoSmithKlein(GSK), 5, Kadmon Corporation, 5, Medpace, 5, Mitsubishi Tanabe, 5, Prometheus, 5; K. Lakin: None; D. Lebiedz-Odrobina: None; Y. Luo: None; J. Molitor: None; D. Moore: None; C. Richardson: None; N. Sandorfi: None; A. Shah: Arena Pharmaceuticals, 5, Eicos Sciences, 5, Kadmon Corporation, 5, Medpace LLC, 5; A. Shah: None; V. Shanmugam: None; B. Skaug: None; V. Steen: None; E. Volkmann: Boehringer-Ingelheim, 2, 5, 6, CSL Behring, 2, GlaxoSmithKline, 2, Horizon, 5, Prometheus, 5, Roche, 2; J. Gordon: Cumberland Pharmaceuticals, 5, Prometheus Pharmaceuticals, 5.

To cite this abstract in AMA style:

Lamba I, Makol A, Khanna D, VanBuren J, Child A, Alvey J, Assassi S, Bernstein E, Castelino F, Chung L, Evnin L, Frech T, Hant F, Hummers L, Lakin K, Lebiedz-Odrobina D, Luo Y, Molitor J, Moore D, Richardson C, Sandorfi N, Shah A, Shah A, Shanmugam V, Skaug B, Steen V, Volkmann E, Gordon J. Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/physical-and-mental-health-in-early-systemic-sclerosis-baseline-results-for-patient-reported-outcomes-measurement-information-system-29-from-the-collaborative-national-quality-and-efficacy-registry/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physical-and-mental-health-in-early-systemic-sclerosis-baseline-results-for-patient-reported-outcomes-measurement-information-system-29-from-the-collaborative-national-quality-and-efficacy-registry/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology